NTRA vs. UTHR: Natera vs. United Therapeutics Stock Comparison
How do Natera (NTRA) and United Therapeutics (UTHR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Natera (NTRA) and United Therapeutics (UTHR) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | NTRA | UTHR |
|---|---|---|
| Name | Natera, Inc. | United Therapeutics Corporation |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 45.05 billion USD | 23.94 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | July 1, 2015 | June 17, 1999 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | NTRA | UTHR |
|---|---|---|
| Total Return (1Y) | 61.03% | 28.77% |
| Total Return (3Y, Annualized) | 92.02% | 37.63% |
| Total Return (5Y, Annualized) | 23.20% | 23.78% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Natera (NTRA) has an aggressive beta of 1.58, indicating higher sensitivity to broad-market moves, while United Therapeutics (UTHR) is defensive at 0.49 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.
| Metric | NTRA | UTHR |
|---|---|---|
| Volatility (1Y, Annualized) | 52.30% | 35.00% |
| Beta (5Y) | 1.58 | 0.49 |
| Max Drawdown (5Y) | -75.72% | -33.00% |
| Avg. Volume (3M) | 1.68M | 694.55K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | NTRA | UTHR |
|---|---|---|
| Sharpe Ratio (1Y) | 1.09 | 0.70 |
| Sortino Ratio (1Y) | 1.63 | 1.29 |
Profitability
ROE (TTM)
Natera (NTRA) reports a negative ROE of -10.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile United Therapeutics (UTHR) reports 19.13%, ranking against industry peers normally.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-10.55%
- Max
- 109.18%
- Q3
- 6.23%
- NTRA
- -10.55%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.13%
- Max
- 109.18%
- UTHR
- 19.13%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Natera (NTRA) reports a negative net margin of -5.66%, usually indicating a net loss over the period. Meanwhile United Therapeutics (UTHR) reports 38.61%, ranking against industry peers normally.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-5.66%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- NTRA
- -5.66%
- Min
- -17.05%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
38.61%
- UTHR
- 38.61%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Natera (NTRA) reports a negative operating margin of -7.64%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile United Therapeutics (UTHR) reports 28.99%, ranking against industry peers normally.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-7.64%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- NTRA
- -7.64%
- Q1
- -78.82%
- Min
- -207.40%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.99%
- Max
- 83.12%
- UTHR
- 28.99%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | NTRA | UTHR |
|---|---|---|
| ROE (TTM) | -10.55% | 19.13% |
| ROA (TTM) | -6.79% | 10.91% |
| Net Margin (TTM) | -5.66% | 38.61% |
| Operating Margin (TTM) | -7.64% | 28.99% |
| Gross Margin (TTM) | 65.14% | 86.34% |
Growth
Revenue Growth
Both Natera (NTRA) at 35.90% and United Therapeutics (UTHR) at 10.61% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: United Therapeutics (UTHR) reports EPS growth of 13.07%, ranked against its industry; Natera (NTRA) has no EPS growth figure this period.
Growth Metrics
| Metric | NTRA | UTHR |
|---|---|---|
| Revenue Growth (YoY) | 35.90% | 10.61% |
| Revenue Growth (3Y CAGR) | 41.14% | 18.02% |
| EPS Growth (YoY) | -- | 13.07% |
| EPS Growth (3Y CAGR) | -- | 22.92% |
Financial Strength
Current Ratio (MRQ)
Both Natera (NTRA) at 2.81 and United Therapeutics (UTHR) at 4.61 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.81
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- NTRA
- 2.81
- Q1
- 2.47
- Min
- 0.10
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.61
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- UTHR
- 4.61
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Natera (NTRA) carries debt-to-equity ratio of 0.13 against its industry range, while United Therapeutics (UTHR) reports no figure this period.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.13
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- NTRA
- 0.13
- Q1
- 0.02
- Min
- 0.00
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- UTHR
- --
Financial Strength Metrics
| Metric | NTRA | UTHR |
|---|---|---|
| Current Ratio (MRQ) | 2.81 | 4.61 |
| Debt / Equity (MRQ) | 0.13 | -- |
| Net Debt / EBITDA | -- | -1.53 |
Dividends
Dividend Yield (TTM)
Neither Natera (NTRA) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NTRA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- UTHR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Natera (NTRA) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NTRA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- UTHR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | NTRA | UTHR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: United Therapeutics (UTHR) trades at 21.22 times trailing earnings, ranked against its peers, while Natera (NTRA) has no P/E ratio this period.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- NTRA
- --
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.22
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- UTHR
- 21.22
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Natera (NTRA) at 15.49 and United Therapeutics (UTHR) at 7.51 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.49
- Max
- 58.18
- Q3
- 25.77
- NTRA
- 15.49
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.51
- Max
- 58.18
- Q3
- 25.77
- UTHR
- 7.51
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
United Therapeutics (UTHR) at 3.80 sits near its industry’s typical P/B ratio, while Natera (NTRA) at 23.99 prices above its benchmark range — NTRA looks rich relative to book.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.99
- NTRA
- 23.99
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.80
- Max
- 13.53
- Q3
- 6.54
- UTHR
- 3.80
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | NTRA | UTHR |
|---|---|---|
| P/E Ratio (TTM) | -- | 21.22 |
| P/S Ratio (TTM) | 15.49 | 7.51 |
| P/B Ratio (MRQ) | 23.99 | 3.80 |
| Free Cash Flow Yield (TTM) | 0.19% | 1.90% |